Despite the fact that HER2 status in cancers of the female reproductive system has been explored for more than 20 years, the determination of HER2 gene status has not been widely recognized as a prognostic biomarker for response to anti-HER2 treatment in gynecologic cancers, unlike in the breast and the digestive system [49]. The gene discussed is ERBB2; the disease is cancer.